Pluri Partners with Kadimastem to Advance Cell Therapy Products for Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Pluri Inc. (NASDAQ:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. to produce cell therapy products for ALS and diabetes treatments. PluriCDMO™ will manufacture AstroRx® and IsletRx for upcoming clinical trials.

July 18, 2024 | 6:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pluri Inc. has entered into a significant partnership with Kadimastem to manufacture cell therapy products for ALS and diabetes treatments, leveraging its GMP cell production facility.
The partnership with Kadimastem to manufacture cell therapy products for clinical trials is a significant development for Pluri Inc. This collaboration leverages Pluri's GMP cell production facility and expertise, potentially leading to increased revenue and market recognition.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100